Specialty Pipeline MONTHLY UPDATE

Critical updates in an ever changing environment

September 2019

NEW DRUG INFORMATION

® ●● Harvoni (ledipasvir and sofosbuvir) oral pellets: The U.S. Food and Drug Administration (FDA) approved Gilead’s Harvoni for the treatment of patients aged 3 years and older with certain genotypes of hepatitis C virus. Prior to this approval Harvoni was only approved in pediatric patients 12 years of age and older. In addition to the expanded indication, the FDA approved Harvoni in a pellet formulation and a new strength (45 mg/200 mg). Launch and pricing are pending.

® ●● Sovaldi (sofosbuvir) oral pellets: The FDA expanded the indication of Sovaldi to include pediatric patients 3 years of age and older with certain genotypes of hepatitis C virus. In addition, the FDA approved a new pellet formulation and a new strength (200 mg) of Sovaldi. Launch and pricing are pending.

NEW INDICATIONS

® ●● Taltz (ixekizumab): The FDA approved the subcutaneous injection formulation of Lilly’s Taltz for the treatment of adult patients with active ankylosing spondylitis. Taltz is also approved for moderate to severe plaque psoriasis and active psoriatic arthritis in adults.

® ●● Ofev (): Boehringer Ingelheim received FDA approval for Ofev for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This is the first FDA approval for a treatment for SSc-ILD. OFev is also approved for the treatment of idiopathic pulmonary fibrosis.

® ® ●● Keytruda (pembrolizumab) and Lenvima (): The FDA granted accelerated approval, under Project Orbis, for the combination of Keytruda (Merck) and Lenvima (Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and whose cancer has progressed following prior systemic therapy but are not candidates for curative surgery or radiation. Project Orbis is a collaboration between the FDA and international regulatory partners that provides a framework for concurrent submission and review of oncology drugs. This pathway allowed for the FDA to have an early look at the pivotal data and simultaneous approvals occurring in the U.S., Canada, and Australia.

® ●● Nucala (mepolizumab): The FDA expanded GSK’s Nucala indication for severe eosinophilic asthma add-on maintenance treatment to include pediatric patients aged 6 to 11 years. Nucala is the only targeted biologic to be approved for this condition in this age group in the U.S.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner. Specialty Pipeline Monthly Update: September 2019 Page 2

SEPTEMBER NEWS

●● “A panel of outside advisers recommended that the FDA greenlight a proposed treatment for peanut allergies in children, a step that could clear the way for marketing the first approved treatment of the condition.”1

●● “Tricida, a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that it has submitted a New Drug Application (NDA) to the FDA under the Accelerated Approval Program for approval of veverimer for the treatment of metabolic acidosis in patients with CKD.” 2

●● “Global Blood Therapeutics, Inc. announced that the FDA has accepted for filing the company’s NDA seeking accelerated approval for voxelotor, an oral, once-daily therapy in development for the treatment of sickle cell disease (SCD).”3 Specialty Pipeline Monthly Update: September 2019 Page 3

SPECIALTY NEW PRODUCT APPROVALS IN THE PAST TWELVE MONTHS ROUTE OF MONTH GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED ledipasvir and Harvoni® Gilead Hepatitis C Oral September 2019 sofosbuvir pellets sofosbuvir pellets Sovaldi® Gilead Hepatitis C Oral September 2019

lefamulin Xenleta™ Nabriva Community acquired bacterial Oral and IV August 2019 pneumonia upadacitinb Rinvoq™ Abbvie Rheumatoid arthritis Oral August 2019

pretomanid Pretomanid Global Alliance Tuberculosis Oral August 2019 for TB immune globulin subcutaneous, Xembify™ Grifols SA Primary humoral SC July 2019 human-klhw immunodeficiency bremelanotide Vyleesi™ AMAG Generalized hypoactive sexual SC June 2019 Pharmaceuticals desire disorder and Palatin Technologies onasemnogene Zolgensma™ Novartis/Avexis SMA in pediatrics < 2 years IV May 2019 abeparvovec-xioi of age Ruzurgi™ Jacobus Lambert-Eaton myasthenic Oral May 2019 Pharmaceutical syndrome (LEMS) Company tafamidis Vyndaqel™ Heart disease caused by Oral May 2019 mediated (ATTR-CM) tafamidis Vydamax™ Pfizer ATTR-CM Oral May 2019

risankizumab-rzaa Skyrizi® Abbvie Plaque psoriasis SC April 2019

romosozumab-aqqg Evenity® Amgen and UCB Osteoporosis SC April 2019

immune globulin intravenous Asceniv® ADMA Biologics Primary humoral IV April 2019 human-slra) immunodeficiency cladribine Mavenclad™ EMD Serono (Merck Multiple sclerosis (MS) Oral March 2019 KGAA) and Ivax siponimod Mayzent® Novartis MS Oral March 2019

esketamine Spravato™ Janssen Treatment-resistant depression Nasal spray March 2019

antihemophilic factor Esperoct™ Novo Nordisk Hemophilia A IV February 2019 (recombinant), glycopegylated-exei caplacizumab-yhdp Cablivi™ Sanofi Acquired thrombotic IV/SC December 2018 thrombocytopenic purpura monomethyl fumarate delayed- Bafiertam™ Banner Life Science Relapsing multiple sclerosis Oral December 2018 release (Tentative approval) immune globulin subcutaneous Cutaquig™ Octapharma Primary humoral SC December 2018 [human]-hipp immunodeficiency levodopa Inbrija™ Accorda Off episodes in Parkinson’s Inhalation December 2018 Therapeutics disease ravulizumab-cwvz Ultromiris™ Alexion Paroxysmal nocturnal IV December 2018 Pharmaceuticals hemoglobinuria

continued Specialty Pipeline Monthly Update: September 2019 Page 4

SPECIALTY NEW PRODUCT APPROVALS IN THE PAST TWELVE MONTHS (continued) ROUTE OF MONTH GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED amifampridine Firdapse™ Catalyst Lambert-Eaton myasthenic Oral November 2018 Pharmaceuticals syndrome (LEMS) emapalumab-lzsg Gamifant™ Novimmune Hemophagocytic IV November 2018 lymphohistiocytosis (HLH) elapegademase-lvlr Revcovi™ Leadiant Adenosine deaminase severe IM October 2018 Pharmaceuticals combined immune deficiency (ADA-SCID) Tegsedi ™ Ionis Polyneuropathy of hereditary SC October 2018 Pharmaceuticals/ transthyretin-mediated Akcea amyloidosis (hATTR)

NEW INDICATIONS FOR APPROVED SPECIALTY PRODUCTS

GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION(S) DATE APPROVED ledipasvir and Harvoni® Gilead Pediatric patients 3 years and above September 2019 sofosbuvir pellets sofosbuvir pellets Sovaldi® Gilead Pediatric patients 3 years and above September 2019

mepolizumab Nucala® GlaxoSmithKline Pediatric patients 6 to 11 years September 2019

nintedanib Ofev® Boehringer Systemic sclerosis-associated interstitial September 2019 Ingelheim lung disease ixekizumab Taltz ® Lilly Active ankylosing spondylitis August 2019

bedaquiline Sirturo® Johnson & Pediatric patients 12 years and older August 2019 Johnson apremilast Otezla® Celgene Corp Oral ulcers associated with Behcet’s disease July 2019

deflazacort Emflaza® PTC Therapeutics Expanded age range for the corticosteroid to June 2019 include pediatric patients with Duchenne muscular dystrophy who are between 2 and 5 years old tezacaftor/ivacaftor Symdeko® Vertex CF patients ages 6 and older who are homozygous June 2019 Pharmaceuticals for the F508del mutation or who have at least one mutation in the CF transmembrance conductance regulator gene that is responsive to Symdeko dupilumab Dupixent® Regeneron/Sanofi Severe chronic rhinosinusitis with nasal polyps June 2019

avatrombopag Doptelet® Dova Immune thrombocytopenia (ITP) who have had an June 2019 insufficient response to a previous treatment eculizumab Soliris® Alexion Neuromyelitis optica spectrum disorder (NMOSD) June 2019 Pharmaceuticals Jakafi® Incyte Steroid-refractory acute graft-versus-host disease May 2019 (GVHD) teduglutide, rDNA origin Gattex® Shire Pediatric patients aged 1 to 17 years old with short May 2019 bowel syndrome (SBS) Eylea® Regeneron Diabetic retinopathy May 2019

ivacaftor Kalydeco® Vertex Children as young as six months old with cystic May 2019 Pharmaceuticals fibrosis (CF) who have at least one mutation in the CFTR gene

continued Specialty Pipeline Monthly Update: September 2019 Page 5

NEW INDICATIONS FOR APPROVED SPECIALTY PRODUCTS (continued)

GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION(S) DATE APPROVED glecaprevir and pibrentasvir Mavyret® AbbVie Treatment of six genotypes of hepatitis C virus (HCV) May 2019 in children ages 12 to 17 belimumab Benlysta® GSK Children aged 5 years and older with systemic lupus May 2019 erythematosus (SLE) certolizumab pegol Cimzia® UCB Radiographic axial spondyloarthritis (nr-axSpA) April 2019

dupilumab Dupixent® Sanofi/Regeneron Expand atopic dermatitis indication to patients March 2019 aged 12 – 17 years of age tacrolimus extended-release Envarsus XR® Veloxis Prophylaxis of organ rejection in kidney transplant December 2018

romiplostim Nplate® Amgen Pediatric patients 1 year of age and older with December 2018 chronic ITP recombinant antihemophilic Novoeight® Novo Nordisk On-demand treatment and control of bleeding November 2018 factor episodes in hemophilia A eltrombopag Promacta® Novartis First-line treatment of severe aplastic anemia (SAA) November 2018

sodium oxybate oral solution Xyrem® Jazz Pediatric narcolepsy patients October 2018 Pharmaceuticals Rituxan® Genentech Microscopic polyangiitis and granulomatosis with October 2018 polyangiitis dupilumab Dupixent® Sanofi/Regeneron Add-on maintenance treatment for patients aged October 2018 12 years and older who have eosinophilic phenotype or oral corticosteroid-dependent moderate to severe asthma emicizumab-kxwh Hemlibra® Roche Hemophilia A without factor VIII inhibitors. October 2018

ONCOLOGY PRODUCT APPROVALS IN THE PAST TWELVE MONTHS ROUTE OF DATE GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED Inrebic™ Celgene Myelofibrosis Oral August 2019

Rozlytrek™ Genentech ROS1-positive non-small cell Oral August 2019 lung cancer (NSCLC) and certain NTRK gene fusion cancers Turalio™ Daiichi Sankyo Symptomatic tenosynovial giant Oral August 2019 cell tumor darolutamide Nubeqa™ Bayer and Orion Non-metastatic castration- Oral July 2019 resistant prostate cancer selinexor Xpovio™ Karyopharm Multiple myeloma Oral July 2019

polatuzumab vedotin-piiq Polivy™ Genentech Relapsed or refractory diffuse IV June 2019 large B-cell lymphoma fulvestrant Fulvestrant™ Kabi USA Breast cancer IV May 2019

alpelisib Piqray™ Novartis Breast cancer Oral May 2019

Balversa™ Janssen Locally advanced or metastatic Oral April 2019 bladder cancer and Herceptin Genentech/ Breast cancer SC February 2019 hyaluronidase-oysk Hylecta™ Halozyme

continued Specialty Pipeline Monthly Update: September 2019 Page 6

ONCOLOGY PRODUCT APPROVALS IN THE PAST TWELVE MONTHS (continued) ROUTE OF DATE GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED calaspargase pegol-mknl Asparlas™ Shire Acute lymphoblastic leukemia IV December 2018 (ALL) tagraxofusp-erzs Elzonris™ Stemline Blastic plasmacytoid dendritic IV December 2018 Therapeutics cell neoplasm Xospata™ Astellas Relapsed or refractory (r/r) Oral November 2018 acute myeloid leukemia (AML) Vitrakvi™ Loxo Oncology Solid tumors with NTRK gene Oral November 2018 fusion glasdegib Daurismo™ Pfizer AML patients > 75 years old Oral November 2018

Lorbrena™ Pfizer Metastatic non-small cell lung Oral November 2018 cancer (NSCLC) talazoparib Talzenna™ Pfizer Locally advanced or metastatic Oral October 2018 breast cancer Specialty Pipeline Monthly Update: September 2019 Page 7

NEW INDICATIONS FOR APPROVED ONCOLOGY DRUGS

GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION DATE APPROVED apalutamide Erleada Janssen Metastatic castration-sensitive prostate September 2019 cancer pembrolizumab and lenvatinib Keytruda and Merck and Eisai Certain forms of advanced endometrial September 2019 Lenvima carcinoma pembrolizumab Keytruda® Merck Certain types of squamous cell carcinoma August 2019 of the esophagus lenalidomide Revlimid® Celgene In combination with rituximab for follicular June 2019 lymphoma or marginal zone lymphoma rituximab-abbs Truxima® Celltrion CD20-positve non-Hodgkin’s lymphoma June 2019

ado- Kadcyla® Genentech/Roche HER2+ early breast cancer June 2019

daratumumab Darzalex Janssen In combination with lenalidomide and June 2019 dexamethasone for multiple myeloma pembrolizumab Keytruda Merck Head and neck squamous cell carcinoma June 2019

ramucirumab Cyramza® Eli Lilly Hepatocellular carcinoma (HCC) May 2019

Venclexta® Genentech and Untreated patients with chronic May 2019 Abbvie lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Tibsovo® Agios Individuals aged 75 years or older with May 2019 newly diagnosed AML who have isocitrate dehydrogenase-1 (IDH1) mutations as detected by an FDA-approved test or are ineligible for intensive induction chemotherapy avelumab Bavencio® EMD Serono Combination with PF Prism CV’s Inlyta® May 2019 () for the first-line treatment of patients with advanced renal cell carcinoma (RCC). pembrolizumab Keytruda® Merck Patients with stage III NSCLC who are April 2019 not candidates for surgical resection or definitive chemoradiation along with metastatic NSCLC patients, the PD-L1 threshold is now set at a tumor proportion score (TPS) of 1% or higher pembrolizumab Keytruda® Merck Renal cell carcinoma April 2019

albociclib Ibrance® Pfizer Breast cancer in males April 2019

ivosidenib Tibsovo® Agios Acute myeloid leukemia (AML) for April 2019 Pharmaceuticals Inc patients who are at least 75 years old or have comorbidities erdafitinib Balversa® Janssen Urothelial carcinoma April 2019 Pharmaceuticals Companies atezolizumab Tecentriq® Genentech First-line treatment of adults with March 2019 extensive-stage small cell lung cancer atezolizumab Tecentriq® Genentech With Abraxane (nab-paclitaxel) March 2019 chemotherapy for first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) that expresses PD-L1

continued Specialty Pipeline Monthly Update: September 2019 Page 8

NEW INDICATIONS FOR APPROVED ONCOLOGY DRUGS (continued)

GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION DATE APPROVED trifluridine/tipiracil Lonsurf® Taiho Metastatic gastric or gastroesophageal February 2019 junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy pembrolizumab Keytruda® Merck Adjuvant treatment of melanoma February 2019

Imbruvica® Janssen/AbbVie Previously untreated adult CLL/SLL January 2019

Cabometyx® Exelixis Previously treated HCC January 2019

Sprycel® BMS First-line in pediatric patients with newly January 2019 diagnosed Philadelphia chromosome- positive ALL (Ph+ ALL) olaparib Lynparza® AstraZeneca/Merck Maintenance therapy for deleterious or December 2019 suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer atezolizumab Tecentriq® Roche With Avastin®, paclitaxel and carboplatin December 2018 for first-line treatment of NSCLC pembrolizumab Keytruda® Merck Advanced hepatocellular carcinoma (HCC) November 2018

venetoclax Venclexta® Abbvie With azacitidine or decitabine or November 2018 low-dose cytarabine for treatment of newly-diagnosed AML in adult patients who are > 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy Adcetris® Seattle Genetics With chemotherapy for certain adults November 2018 with peripheral T-cell lymphomas (PTCL) in the first-line setting

BIOSIMILAR PRODUCT APPROVALS IN THE PAST TWELVE MONTHS REFERENCE ROUTE OF MONTH GENERIC NAME BRAND NAME PRODUCT MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED adalimumab-bwwd Hadlima™ Humira® Samsung Bioepis/Merck Certain forms of: SC July 2019 rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, plaque psoriasis rituximab-pvvr Ruxience™ Rituxan® Pfizer Certain forms of: non- IV July 2019 Hodgkin’s lymphoma, chronic lymphocytic leukemia, granuloma­ tosis with polyangiitis

continued Specialty Pipeline Monthly Update: September 2019 Page 9

BIOSIMILAR PRODUCT APPROVALS IN THE PAST TWELVE MONTHS (continued) REFERENCE ROUTE OF MONTH GENERIC NAME BRAND NAME PRODUCT MANUFACTURER INDICATION(S) ADMINISTRATION APPROVED bevacuzynav-bvzr Zirabev™ Avastin® Pfizer Certain forms of IV July 2019 metastatic colorectal cancer, metastatic non-squamous non- small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and cervical cancer trastuzumab-anns Kanjinti™ Herceptin® Amgen/Allergan HER2-positive breast IV June 2019 cancer or gastric or gastroesophageal junction cancer etanercept-ykro Eticovo® Enbrel® Samsung Bioepis Rheumatoid arthritis SC April 2019 (RA); polyarticular juvenile idiopathic arthritis (JIA) psoriatic arthritis (PsA); ankylo­ sing spondylitis (AS); plaque psoriasis (PsO) trastuzumab-qyyp Trazimera™ Herceptin® Pfizer HER2-positive breast IV March 2019 cancer or gastric or gastroesophageal junction cancer trastuzumab-dttb Ontruzant® Herceptin® Samsung Bioepis/Merck HER2-positive breast IV December 2018 cancer or gastric or gastroesophageal junction cancer trastuzumab-pkrb Herzuma® Herceptin® Celltrion and Teva HER2-positive breast IV December 2018 cancer rituximab-abbs Truxima™ Rituxan® Celltrion and Teva NHL IV November 2018

pegfilgrastim-cbqv Udenyca™ Neulasta® Coherus BioSciences Neutropenia SC November 2018

adalimumab-adaz Hyrimoz™ Humira® Sandoz/Novartis Autoimmune SC October 2018 Specialty Pipeline Monthly Update: September 2019 Page 10

SPECIALTY PIPELINE ROUTE OF ANTICIPATED GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVAL DATE* crizanlizumab N/A Novartis Sickle cell disease IV September 2019

brolucizumab N/A Novartis Macular degeneration Eye injection October 2019

afamelanotide Scenesse® Clinuvel Erythropoietic protoporphyria SC October 2019 Pharmaceuticals Ltd PF708 (teriparatide) N/A Pfenex/Alvogen Osteoporosis SC October 2019

triamcinolone acetonide Xipere™ Clearside Medical Macular edema with uveitis Eye injection October 2019

methotrexate Reditrex® Cumberland Arthritis/psoriasis SC November 2019 Pharmaceuticals/ Nordic Group BV Exservan® Aquestive ALS Oral film November 2019

RVT-802 N/A Enzyvant Primary immune deficiency Surgical December 2019 resulting from congenital athymia associated with complete DiGeorge Anomaly luspatercept N/A Celegene Corp Beta-thalassemia-associated SC December 2019 anemia who require red blood cell transfusions diroximel fumarate Vumerity™ Alkermes/Biogen Relapsing forms of MS Oral December 2019

betibeglogene darolentivec Zynteglo™ Bluebird Bio Transfusion-dependent IV 2020 beta‑thalassemia inebilizumab N/A Viela Bio Neuromyelitis optica spectrum IV 1H2020 disorder AR101 Palforzia™ Allergy Peanut allergy Oral January 2020

tazemetostat N/A Epizyme Epithelioid sarcoma Oral January 2020

givosiran N/A Alnylam Acute hepatic porphyria SC February 2020

N/A Blueprint Medicines Gastrointestinal stromal tumors Oral February 2020

voxelotor N/A Global Blood Sickle cell disease Oral February 2020 Therapeutics zanubrutinib N/A BeiGene Mantle cell lymphoma Oral February 2020

ozanimod N/A Celgene Corp MS Oral March 2020

enfortumab vedotin N/A Astellas and Urothelial cancer IV March 2020 Seattle Genetics elexacaftor, tezacaftor N/A Vertex Cystic fibrosis Oral March 2020 and ivacaftor cysteamine bitartrate N/A Horizon Nephropathic cystinosis Oral March 2020

teprotumumab N/A Horizon Active thyroid eye disease IV March 2020

luspatercept N/A Celgene Corp Myelodysplastic syndrome SC April 2020 associated anemia isatuximab N/A Sanofi Multiple myeloma IV April 2020

treprostinil for infusion Trevyent ® SteadyMed Drug/device for PAH SC or IV April 2020 with PatchPump device abicipar pegol N/A Allergan Macular degeneration Eye injection July 2020

* Anticipated approval dates are predictions made by Prime Therapeutics based on industry information. Specialty Pipeline Monthly Update: September 2019 Page 11

BIOSIMILAR PIPELINE ROUTE OF ANTICIPATED GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S) ADMINISTRATION APPROVAL DATE*

Autoimmune PF-06410293 (adalimumab) N/A Pfizer Autoimmune SC 4Q2019 (Humira® biosimilar) ABP 710 N/A Amgen Autoimmune IV December 2019 (Remicade® biosimilar)

Blood modifiers LA-EP2006 N/A Sandoz Neutropenia SC October 2019 (Neulasta® biosimilar) TX-01 N/A Tanvex BioPharma Neutropenia IV/SC October 2019 (Neupogen® biosimilar)

WATCH LIST

Criteria for inclusion on the Watch List include: drug is submitted to the FDA and is anticipated to have material impact to trend and/or material impact to preferred product strategies (medical or pharmacy).

ANTICIPATED NET NEW IMPACT NET NEW IMPACT BRAND PROPOSED INDICATION/ APPROVAL SIMILAR TO PMPM* TO PMPM* (GENERIC)/MANUFACTURER ROUTE OF ADMINISTRATION (PDUFA DATE) PRODUCTS PHARMACY BENEFIT MEDICAL BENEFIT Valrox™ (valoctocogene Hemophilia A/IV TBD First gene therapy None TBD roxaparvovec)/Biomarin for hemophilia Zynteglo™/Bluebird Bio Transfusion-dependent TBD Allogenic HSCT None $$ ß-thalassemia/IV ubrogepant/Allergan Acute migraine/oral December 2019 Triptans $$ None rimegepant/Biohaven lasmiditan/Lilly Palforzia (AR101)/ Peanut allergy/ January 2020 Allergist controlled $$ None Aimmune and oral (Palforzia) desensitization and Viaskin Peanut/ patch (Viaskin Peanut) avoidance DBV Technologies *Notations: $ < $0.08 per member per month (PMPM), $$ = $0.08 – $0.39 PMPM, $$$ = $0.40 – $2.00 PMPM, $$$$ > $2.01 PMPM

REFERENCES

1. https://www.wsj.com/articles/peanut-allergy-drug-supported-by-fda-advisory-panel-11568422071. 2. https://www.biospace.com/article/releases/tricida-announces-submission-of-new-drug-application-for-veverimer-for-the-treatment-of-metabolic-acidosis-in-patients-with-chronic-kidney-disease/. 3. https://www.globenewswire.com/news-release/2019/09/05/1911462/0/en/GBT-Announces-U-S-Food-and-Drug-Administration-Acceptance-of-New-Drug-Application-and-Priority-Review-for-Voxelotor-for-the-Treatment-of- Sickle-Cell-Disease.html.

2992-B1 © Prime Therapeutics LLC 09/19